UNCY Stock Forecast: Unicycive Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Unicycive Therapeutics, Inc. is $23. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 36 of 100 as at 18 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Unicycive Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (69): The share price has been relatively steady.
Issuance (21): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
UNCY stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on UNCY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 1 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $15 → $13 |
| 20 Aug 2026 | Benchmark | Maintains | Speculative Buy | $13 → $15 |
| 13 Aug 2026 | B. Riley Securities | Reiterates | Buy | $22 → $20 |
| 13 Aug 2026 | Guggenheim | Maintains | Buy | $37 → $25 |
| 1 July 2026 | Benchmark | Maintains | Speculative Buy | $18 → $13 |
| 1 July 2026 | Noble Capital Markets | Maintains | Outperform | $60 → $50 |
| 30 June 2026 | B. Riley Securities | Maintains | Buy | $22 |
| 30 June 2026 | HC Wainwright & Co. | Maintains | Buy | $22 → $15 |
| 2 June 2026 | Benchmark | Maintains | Speculative Buy | — |
| 13 May 2026 | Guggenheim | Maintains | Buy | — |
| 6 Apr 2026 | Benchmark | Maintains | Speculative Buy | — |
| 2 Apr 2026 | Guggenheim | Maintains | Buy | — |
| 29 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Sept 2025 | Benchmark | Maintains | Speculative Buy | — |
| 27 May 2025 | HC Wainwright & Co. | Assumes | Buy | $9.00 |
| 21 Apr 2025 | Guggenheim | Initiates | Buy | — |
| 11 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Jan 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for UNCY.
This page is one stock. Monday covers all of them.
UNCY appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
UNCY vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Unicycive Therapeutics, Inc. returned −36.2% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
UNCY analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.1×
- EV / EBITDA
- —
Cheaper than 43% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −80.4%
- Return on assets
- −35.9%
- Dividend yield
- —
Higher than 16% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Unicycive Therapeutics, Inc. has a market value of $101.4M and an enterprise value of $49.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$35.2M.
Free cash flow in the twelve months to 30 June 2026: −$27.8M.
forward P/E: 4.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Unicycive Therapeutics, Inc. employs 21 people.
Data provided by Twelve Data
UNCY and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at UNCY’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Unicycive Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about UNCY
What is the UNCY stock price forecast for 2026-2027?
The median 12-month analyst price target for Unicycive Therapeutics, Inc. is $23, with estimates ranging from $13 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is UNCY stock a buy right now?
Of the 10 analysts covering Unicycive Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Unicycive Therapeutics, Inc. 36 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank UNCY?
As at 18 Nov 2026, Unicycive Therapeutics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (69 of 100).
Will UNCY stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts is $23, and Ticker Nerd's factor model ranks Unicycive Therapeutics, Inc. 36 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the UNCY stock forecast for 2030?
No analyst covering Unicycive Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UNCY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $42 over the next 12 months.
How has UNCY stock performed over the past year?
Unicycive Therapeutics, Inc. returned -36.2% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Unicycive Therapeutics, Inc. do?
Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for kidney diseases. Its current pipeline centers on treatments for chronic kidney disease-related hyperphosphatemia and acute kidney injury, including oxylanthanum carbonate, a phosphate-binding agent designed for patients on dialysis, and UNI-494, a drug candidate being studied for kidney injury-related conditions.
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for kidney diseases. Its current pipeline centers on treatments for chronic kidney disease-related hyperphosphatemia and acute kidney injury, including oxylanthanum carbonate, a phosphate-binding agent designed for patients on dialysis, and UNI-494, a drug candidate being studied for kidney injury-related conditions. The company operates in the nephrology-focused biopharmaceutical market, where it works to address unmet medical needs through drug development and commercialization activities. Unicycive Therapeutics also evaluates additional renal and metabolic opportunities, reflecting its focus on specialized therapies for complex kidney conditions.
CEO Dr. Shalabh K. Gupta M.D., MPA · 21 employees · United States · https://unicycive.com